Beijing Mabworks Biotech Co. Ltd.

Chengdu Conmed Biosciences Co., Ltd.

Sijia Huang

Feng Li

Boyan Zhang

Chunyang Jin

Jian Zhao

Pei Ye

Yu Liu

Jiangmei Li

Bo Chen

Gang Xu

Fangjie Liu

Xuhong Chen

Disclosed is a monoclonal antibody that binds human and monkey CD3, or an antigen-binding portion thereof, as well as the use of the antibody or antigen-binding portion thereof in treatment of inflammatory diseases and in preparation of bispecific antibodies. A bispecific antibody against e.g., CD3 and CD20 comprising the antibody or antigen-binding portion thereof of the disclosure, and the use of the bispecific antibody in treatment of diseases such as cancers are also provided.

Antibodies binding human and monkey CD3 and uses thereof

An antibody capable of blocking CD47-SIRPa interaction and an application thereof.

Antibody capable of blocking CD47-SIRPa interaction and application thereof

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies. The present invention also relates to Chinese Hamster ovary (CHO) mutant cell line that has a dysfunctional Slc35C1 gene, which is the only dysfunctional gene in the mutant that affects glycan regulation.

Bispecific anti-HER2 antibody

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chain of pertuzumab. The bispecific anti-HER2 antibodies is effective for treating cancer, such as breast cancer, gastric cancer, or ovarian cancer. Preferred bispecific anti-HER antibodies of the present invention are afucosylated antibodies.

Growing community of inventors

Beijing, China

Sijia Huang